N-(2-hydroxyethyl)-N,N-dimethyl-2,3-bis(oleoyloxy)propan-1-aminium bromide

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: N-(2-hydroxyethyl)-N,N-dimethyl-2,3-bis(oleoyloxy)propan-1-aminium bromide
• 英文别名: 2,3-bis[[(Z)-octadec-9-enoyl]oxy]propyl-(2-hydroxyethyl)-dimethylazanium;bromide
• 化学式: C43H82BrNO5
• 分子量: 773.0
• InChiKey: NNIFGWCTDFSLJC-JDVCJPALSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  8.59
• 重原子数：
  50
• 可旋转键数：
  39
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  72.8
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• Combinations of mRNAs encoding immune modulating polypeptides and uses thereof
  申请人：ModernaTX, Inc.

  公开号：US10172808B2

  公开（公告）日：2019-01-08

  The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of combinations of immunomodulatory polynucleotides (e.g., mRNAs) encoding an immune response primer polypeptide (e.g., an interleukin 23 (IL-23) polypeptide or an interleukin 36γ (IL-36-gamma) polypeptide), and an immune response co-stimulatory signal polypeptide (e.g., an OX40L polypeptide).

  本公开涉及免疫调节多核苷酸（如mRNA）编码免疫应答引物多肽（如白细胞介素23（IL-23）多肽或白细胞介素36γ（IL-36-γ）多肽）和免疫应答共刺激信号多肽（如OX40L多肽）组合的制备、制造和治疗使用的组合物和方法。
• MRNA combination therapy for the treatment of cancer
  申请人：ModernaTX, Inc.

  公开号：US10335486B2

  公开（公告）日：2019-07-02

  The present disclosure relates to the use of nucleic acid (e.g., mRNA) combination therapies for the treatment of cancer. The disclosure provides compositions, and methods for their preparation, manufacture, and therapeutic use, wherein those compositions comprise at least two polynucleotides (e.g., mRNAs) in combination wherein the at least two polynucleotides are selected from the group consisting of (i) a polynucleotide encoding an immune response primer (e.g., IL23), (ii) a polynucleotide encoding an immune response co-stimulatory signal (e.g., OX40L), (iii) a polynucleotide encoding a checkpoint inhibitor (e.g., an anti CTLA-4 antibody), and, (iv) a combination thereof. The therapeutic methods disclosed herein comprise, e.g., the administration of a combination therapy disclosed herein for the treatment of cancer, e.g., by reducing the size of a tumor or inhibiting the growth of a tumor, in a subject in need thereof. In some aspects, the combination therapies disclosed herein disclosed are administered intratumorally.

  本公开涉及使用核酸（如mRNA）组合疗法治疗癌症。本公开提供了组合物及其制备、制造和治疗使用的方法，其中这些组合物包括至少两种组合在一起的多核苷酸（如mRNA），其中至少两种多核苷酸选自由以下组成的组(i)编码免疫应答引物的多核苷酸（如IL23），(ii)编码免疫应答引物的多核苷酸（如IL23），(iii)编码免疫应答引物的多核苷酸（如IL23），(iv)编码免疫应答引物的多核苷酸（如IL23）、IL23），(ii) 编码免疫应答共刺激信号（如 OX40L）的多核苷酸，(iii) 编码检查点抑制剂（如抗 CTLA-4 抗体）的多核苷酸，以及 (iv) 其组合。本文公开的治疗方法包括，例如，在有需要的受试者中施用本文公开的用于治疗癌症的组合疗法，例如，通过减小肿瘤大小或抑制肿瘤生长。在某些方面，本文公开的组合疗法是肿瘤内给药。
• Polynucleotides encoding methylmalonyl-CoA mutase
  申请人：ModernaTX, Inc.

  公开号：US10406112B2

  公开（公告）日：2019-09-10

  The disclosure relates to polynucleotides comprising an open reading frame of linked nucleosides encoding human methylmalonyl-CoA mutase precursor, human methylmalonyl-CoA mutase (MCM) mature form, or functional fragments thereof. In some embodiments, the disclosure includes methods of treating methylmalonic acidemia in a subject in need thereof comprising administering an mRNA encoding an MCM polypeptide.

  本公开涉及多核苷酸，其包含编码人甲基丙二酰-CoA 突变酶前体、人甲基丙二酰-CoA 突变酶（MCM）成熟形式或其功能片段的连接核苷酸开放阅读框。在一些实施方案中，本公开包括治疗有需要的受试者的甲基丙二酸血症的方法，包括给药编码 MCM 多肽的 mRNA。
• Polynucleotides encoding interleukin-12 (IL12) and uses thereof
  申请人：ModernaTX, Inc.

  公开号：US10646549B2

  公开（公告）日：2020-05-12

  The present disclosure relates to polynucleotides comprising an open reading frame of linked nucleosides encoding human interleukin-12 (IL12), functional fragments thereof, and fusion proteins comprising IL12. In some embodiments, the open reading frame is sequence-optimized. In particular embodiments, the disclosure provides sequence-optimized polynucleotides comprising nucleotides encoding the polypeptide sequence of human IL12, or sequences having high sequence identity with those sequence optimized polynucleotides.

  本公开涉及包含编码人白细胞介素-12（IL12）的连接核苷开放阅读框的多核苷酸、其功能片段以及包含IL12的融合蛋白。在某些实施方案中，开放阅读框是序列优化的。在特定的实施方案中，本公开提供了序列优化的多核苷酸，包括编码人IL12多肽序列的核苷酸，或与这些序列优化的多核苷酸具有高序列同一性的序列。
• Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof
  申请人：ModernaTX, Inc.

  公开号：US11421011B2

  公开（公告）日：2022-08-23

  The present disclosure relates to polynucleotides encoding tethered interleukin-12 (IL-12) polypeptides comprising an IL-12 polypeptide and a membrane domain. The present disclosure also relates to vectors comprising the polynucleotides; host cells comprising the polynucleotides or vectors, polypeptides encoded by the polynucleotides; compositions comprising the polynucleotides, vectors, host cells, or polypeptides and a delivery agent; and uses thereof, including treatment of cancer.

  本公开涉及编码系链白细胞介素-12（IL-12）多肽的多核苷酸，该多肽由IL-12多肽和膜结构域组成。本公开内容还涉及包含多核苷酸的载体；包含多核苷酸或载体、多核苷酸编码的多肽的宿主细胞；包含多核苷酸、载体、宿主细胞或多肽和递送剂的组合物；及其用途，包括治疗癌症。